ARS Pharmaceuticals, Inc 10-Q for FY2026 Q3
ARS Pharmaceuticals, Inc. (SPRY)
10-Q
2026-11-05
For: 2026-09-30
View Original
Added on
November 05, 2026
About this 10-Q
ARS Pharmaceuticals, Inc filed this 10-Q on November 5, 2026, covering the quarter ended September 30, 2026 (FY2026 Q3).
ARS Pharmaceuticals reported nine-month 2026 revenue of $94.0 million, versus $56.2 million in 2025, and net loss of $158.5 million. neffy generated $77.1 million in U.S. net product revenue, while cash, cash equivalents and short-term investments totaled $138.4 million at September 30, 2026. AI summary
Headline figures
Quarter ended September 30, 2026, as reported in this filing, compared with the same period a year earlier where the filing states it.
- Revenue
- $37.71M
- up 16.0% from $32.5M a year earlier
- Net loss
- $35.59M
- compared with a net loss of $51.15M a year earlier
- Diluted EPS
- -$0.36
- compared with -$0.52 a year earlier